pre-update Archives

Blog

Stop if you don’t have an unambiguous drug effect for your new molecular entity!

As a pharmacologist, I’ve always been curious about how drugs work. A favorite time-killer while…

CertaraAugust 18, 2023

Conference

CDISC China Interchange

CertaraAugust 17, 2023

Publication

Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases

Successful clinical development of new therapeutic interventions is notoriously difficult, especially in neurodegenerative diseases, where…

CertaraAugust 15, 2023

On-Demand Webinar

IRA impacts: First 10 drugs selected for the Drug Price Negotiation Program

The Inflation Reduction Act (enacted in August 2022) contains profound changes for the healthcare and…

CertaraAugust 15, 2023

Blog

Secondary Intelligence™: Empowering Decision-Making in Drug Development & Safety Assessment

Adverse effects of drugs pose potential harm to patients and can hinder or halt the…

CertaraAugust 11, 2023

Blog

Model-Informed Formulation Development: Insights from a Case Study

In a captivating webinar led by industry experts, Dr. Swati Jaiswal, Senior PBPK Consultant at…

CertaraAugust 10, 2023

Announcement

Certara collaborates with Korea Institute of Toxicology to ensure FDA submission-ready SEND dataset

Software will aid optimizing pre-clinical data management in accordance with global standards and guidelines. Seoul,…

CertaraAugust 3, 2023

Blog

Drug Manufacturers’ Recent Drop in Insulin Prices in the United States

The prevalence of diabetes in the US is incredibly high and affects more than 10%…

CertaraAugust 3, 2023

On-Demand Webinar

How value communication can make or break your commercial success?

Are you struggling to effectively communicate the value of your products or services in today's…

CertaraAugust 2, 2023

Announcement

Certara and Drugs for Neglected Diseases initiative (DNDi) Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients

DNDi Utilizing Pinnacle 21 Enterprise (P21E), Certara’s Data Science platform for Biostatistics, Data Management, and…

CertaraJuly 31, 2023

pre-update

Stop if you don’t have an unambiguous drug effect for your new molecular entity!

CDISC China Interchange

Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases

IRA impacts: First 10 drugs selected for the Drug Price Negotiation Program

Secondary Intelligence™: Empowering Decision-Making in Drug Development & Safety Assessment

Model-Informed Formulation Development: Insights from a Case Study

Certara collaborates with Korea Institute of Toxicology to ensure FDA submission-ready SEND dataset

Drug Manufacturers’ Recent Drop in Insulin Prices in the United States

How value communication can make or break your commercial success?

Certara and Drugs for Neglected Diseases initiative (DNDi) Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients

Newsletter sign up

Quick links

Solutions

Contact